glp 1 drugs and gastroparesis GLP-1 Manufacturers Argue Lawsuits Should Require Contemporaneous Diagnostic Testing GLP1 and GIP Receptor Agonists:

Advances in incretin-based therapies for MAFLD: mechanisms and clinical evidence

GLP-1s may also improve cognitive health and recall in some people, thanks to their impact on inflammation in the brain and other dementia risk factors

Semaglutide and tirzepatide lead to 1520% weight loss, but surgery averages 2535% with longer durability

But its still important to confirm that dual agonist drugs like tirzepatide can offer similar or even potentially greater cardiovascular benefits (in theory, it was possible that one of the ingredients could have negatively affected the heart)

Battery and data usage also matter

check with your provider